Skip to content
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Advanced
  • Differential activation of bas...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Permanent link
Differential activation of basal and IL-7-induced PI3K/Akt/mTOR and JAK/STAT5 signaling distinguishes pediatric from adult acute lymphoblastic leukemia

Differential activation of basal and IL-7-induced PI3K/Akt/mTOR and JAK/STAT5 signaling distinguishes pediatric from adult acute lymphoblastic leukemia

Not available.

Bibliographic Details
Main Authors: Marta B. Fernandes, A. Margarida Gomes, Mariana L. Oliveira, Joana Caldas, Paulo Lúcio, Rathana Kim, Aurélie Caye-Eude, Filomena Pereira, Aida B. de Sousa, Alessia De Stefano, Matilde Y. Follo, Maria V. Soares, João F. Lacerda, Joana Desterro, Hélène Cavé, Emmanuelle Clappier, Ximo Duarte, Patrícia Ribeiro, João T. Barata
Format: Article
Language:English
Published: Ferrata Storti Foundation 2024-04-01
Series:Haematologica
Online Access:https://haematologica.org/article/view/11562
  • Holdings
  • Description
  • Similar Items
  • Staff View

Internet

https://haematologica.org/article/view/11562

Similar Items

  • Ikaros deficiency is associated with aggressive BCR-ABL1 B-cell precursor acute lymphoblastic leukemia independent of the lineage and developmental origin
    by: Célestine Simand, et al.
    Published: (2021-09-01)
  • Novel Diagnostic and Therapeutic Options for KMT2A-Rearranged Acute Leukemias
    by: Bruno A. Lopes, et al.
    Published: (2022-06-01)
  • mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges
    by: Zhilin Zou, et al.
    Published: (2020-03-01)
  • JAK and mTOR inhibitors prevent cytokine release while retaining T cell bispecific antibody in vivo efficacy
    by: Christian Klein, et al.
    Published: (2022-01-01)
  • Amino acid response by Halofuginone in Cancer cells triggers autophagy through proteasome degradation of mTOR
    by: Carlo Follo, et al.
    Published: (2019-05-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs